On Oct. 20, 2022, published results supported previous findings that the recombinant zoster vaccine Shingrix, recommended by the Centers for Disease Control and Prevention (CDC) for preventing shingles and its complications, is safe and unlikely to cause a serious reaction in healthy adults.

The study, led by Kaiser Permanente Washington Health Research Institute (KPWHRI) Senior Investigator Jen Nelson, PhD, with Senior Investigator Lisa Jackson, MD, MPH, was published in the American Journal of Epidemiology.

The findings bolster safety data from efficacy trials done before the vaccine was licensed and unsolicited reports from clinicians or people who received a vaccination shortly after the vaccine was rolled out in 2018.